Psychiatry Research
Volume 170, Issue 2 , Pages 161-167, 30 December 2009

Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: A multidimensional data-driven approach

  • Ilya A. Lipkovich

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • Corresponding Author InformationCorresponding authors. Lipkovich is to be contacted at Tel.: +1 317 651 6095; fax: +1 317 276 7100. Kollack-Walker, Tel.: +1 317 433 4654; fax: +1 317 276 7100.
  • ,
  • Walter Deberdt

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
  • ,
  • John G. Csernansky

      Affiliations

    • Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63110, USA
    • Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
  • ,
  • Peter Buckley

      Affiliations

    • Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA
  • ,
  • Joseph Peuskens

      Affiliations

    • The Catholic University of Leuven, University Centre St Jozef, Kortenberg, Belgium
  • ,
  • Sara Kollack-Walker

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • Corresponding Author InformationCorresponding authors. Lipkovich is to be contacted at Tel.: +1 317 651 6095; fax: +1 317 276 7100. Kollack-Walker, Tel.: +1 317 433 4654; fax: +1 317 276 7100.
  • ,
  • Matthew Rotelli

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
  • ,
  • John P. Houston

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA

Received 28 September 2007; received in revised form 13 February 2008; accepted 19 September 2008.

Abstract 

The study's goal was to characterize the typology of patient outcomes based on social and occupational functioning and psychiatric symptoms following antipsychotic drug treatment, and to explore predictors of group membership representing the best/worst outcomes. A hierarchical cluster analysis was used to define groups of patients (n=1449) based on endpoint values for psychiatric symptoms, social functioning, and useful work measured up to 30 weeks of treatment. Stepwise logistic regression was used to construct predictive models of cluster membership for baseline predictors, and with 2/4/8 weeks of treatment. Five distinct clusters of patients were identified at endpoint (Clusters A–E). Patients in Cluster A (25.6%, best outcome) had minimal psychiatric symptoms and mild functional impairment, while patients in Cluster D (14.3%) and E (14.8%) (worst outcome) had moderate-to-severe symptoms and severe functional impairment. Occupational functioning, disorganized thinking, and positive symptoms were sufficient to describe the clusters. Membership in the best/worst clusters was predicted by baseline scores for functioning and symptom severity, and by early changes in symptoms with treatment. Psychiatric symptoms and functioning provided complementary information to describe treatment outcomes. Early symptom response significantly improved the prediction of outcome, suggesting that early monitoring of treatment response may be useful in clinical practice.

Keywords: Psychiatric symptoms, Functioning, Cluster analysis, Antipsychotic

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work has been previously presented at scientific meetings including the American Society for Experimental NeuroTherapeutics Annual Conference in Washington, DC, March 3–5, 2005; Society of Biological Psychiatry Annual Conference in Atlanta, GA, May 19–21, 2005; and New Clinical Drug Evaluation Unit Annual Conference in Boca Raton, FL, June 6–9, 2005.

PII: S0165-1781(08)00311-9

doi:10.1016/j.psychres.2008.09.004

Psychiatry Research
Volume 170, Issue 2 , Pages 161-167, 30 December 2009